MCL Featured Stories

Alicia Algeciras-Schimnich, Ph.D., discusses Mayo Clinic Laboratories’ new noninvasive plasma biomarker assay for Alzheimer’s disease, an accessible, highly accurate testing option for individuals age 50 and above who are experiencing mild cognitive impairment or early dementia. Positive test results can confirm amyloid beta pathology and facilitate access to disease-modifying therapies.

PACE/FL - This webinar will cover the laboratory tests available at Mayo Clinic Laboratories to monitor patients using monoclonal antibody therapies for treatment of inflammatory bowel disease. Focus will be shared between analytical approaches as well as literature and practice recommendations for test results interpretation.

Bobbi Pritt, M.D., explains how Mayo Clinic Laboratories' new assay identifies less-common tick-borne bacteria in whole blood. The assay is recommended when tick-borne bacterial infection is suspected but standard testing is unrevealing.

Linda Hasadsri, M.D., Ph.D., and Huong T. Cabral, M.S., C.G.C., explain how Mayo Clinic Laboratories' targeted test panel facilitates accurate diagnosis of hereditary pancreatitis, which heightens the risk for pancreatic cancer. Test results can guide cancer monitoring for patients and their families.

In this episode of Mayo Clinic Laboratories’ “Leveraging the Laboratory” podcast, host Jane Hermansen, outreach manager at Mayo Clinic Laboratories, speaks with Dan Nelson, a Mayo Clinic contract employee and laboratory connectivity expert. They discuss the unique needs and challenges that outreach labs face with information technology (IT) systems.

Wei Shen, Ph.D., and Rhianna Urban, M.S., CGC, explain how Mayo Clinic Laboratories' gene panel establishes a diagnosis of Lynch syndrome, which heightens the risk for several cancers. Test results can guide targeted cancer surveillance for patients and their families.

With many organizations using a digital-first approach, it is easy to assume that is always the best option. But is it? And what about for your laboratory outreach program? Laboratories should consider these seven S’s when deciding whether connectivity will align with the goals of their outreach programs.

Mary Jo Williamson, chief administrative officer of Mayo Clinic Laboratories, joins “Becker’s Healthcare Podcast” to discuss organizational alignment during times of change. She shares her expertise on creating transparency, fostering open communication, and using data to stay on track with business goals.

Since 1992, cases of colorectal cancer have been on a slow decline, yet 52,550 people died from it in 2023. At Mayo Clinic, a cutting-edge menu of both germline (inherited genetic alterations) and somatic (tumors due to non-inherited genetic alterations) testing are two critical tools helping to improve targeted treatments for colorectal and other common gastrointestinal cancers.

P.A.C.E./Florida
Implementation of new analyzers and replacement of automation equipment in the Central Clinical Laboratory at Mayo Clinic in Rochester, Minnesota, prompted the laboratory to reassess blood collection volumes for commonly ordered tests.

Tobacco use is the leading cause of preventable death in the United States. In this test-specific episode of the "Answers From the Lab" podcast, Paul Jannetto, Ph.D., explains how Mayo Clinic Laboratories' nicotine testing benefits patients in smoking cessation programs and other settings.

Dr. Linda Hasadsri’s firsthand encounter with the genetic tests she’s helped develop has provided rare insight into testing quality and implications, enhancing their ability to advocate for the value of testing and infusing their work with deep empathy.

Short, interactive case studies from Mayo Clinic physicians, scientists, and allied health staff